Cargando…
Dupilumab, an emerging therapeutic choice for recalcitrant subepidermal autoimmune bullous diseases: a case series of three patients
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Libbey Eurotext
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8853335/ https://www.ncbi.nlm.nih.gov/pubmed/35107075 http://dx.doi.org/10.1684/ejd.2021.4190 |
| _version_ | 1784653210538999808 |
|---|---|
| author | Liu, Xiuting Ma, Jianchi Qiu, Xiaonan Hong, Dan Wang, Liangchun Shi, Zhenrui |
| author_facet | Liu, Xiuting Ma, Jianchi Qiu, Xiaonan Hong, Dan Wang, Liangchun Shi, Zhenrui |
| author_sort | Liu, Xiuting |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8853335 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | John Libbey Eurotext |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-88533352022-02-18 Dupilumab, an emerging therapeutic choice for recalcitrant subepidermal autoimmune bullous diseases: a case series of three patients Liu, Xiuting Ma, Jianchi Qiu, Xiaonan Hong, Dan Wang, Liangchun Shi, Zhenrui Eur J Dermatol Correspondence John Libbey Eurotext 2022-02-17 2021 /pmc/articles/PMC8853335/ /pubmed/35107075 http://dx.doi.org/10.1684/ejd.2021.4190 Text en © JLE/Springer 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Correspondence Liu, Xiuting Ma, Jianchi Qiu, Xiaonan Hong, Dan Wang, Liangchun Shi, Zhenrui Dupilumab, an emerging therapeutic choice for recalcitrant subepidermal autoimmune bullous diseases: a case series of three patients |
| title | Dupilumab, an emerging therapeutic choice for recalcitrant subepidermal autoimmune bullous diseases: a case series of three patients |
| title_full | Dupilumab, an emerging therapeutic choice for recalcitrant subepidermal autoimmune bullous diseases: a case series of three patients |
| title_fullStr | Dupilumab, an emerging therapeutic choice for recalcitrant subepidermal autoimmune bullous diseases: a case series of three patients |
| title_full_unstemmed | Dupilumab, an emerging therapeutic choice for recalcitrant subepidermal autoimmune bullous diseases: a case series of three patients |
| title_short | Dupilumab, an emerging therapeutic choice for recalcitrant subepidermal autoimmune bullous diseases: a case series of three patients |
| title_sort | dupilumab, an emerging therapeutic choice for recalcitrant subepidermal autoimmune bullous diseases: a case series of three patients |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8853335/ https://www.ncbi.nlm.nih.gov/pubmed/35107075 http://dx.doi.org/10.1684/ejd.2021.4190 |
| work_keys_str_mv | AT liuxiuting dupilumabanemergingtherapeuticchoiceforrecalcitrantsubepidermalautoimmunebullousdiseasesacaseseriesofthreepatients AT majianchi dupilumabanemergingtherapeuticchoiceforrecalcitrantsubepidermalautoimmunebullousdiseasesacaseseriesofthreepatients AT qiuxiaonan dupilumabanemergingtherapeuticchoiceforrecalcitrantsubepidermalautoimmunebullousdiseasesacaseseriesofthreepatients AT hongdan dupilumabanemergingtherapeuticchoiceforrecalcitrantsubepidermalautoimmunebullousdiseasesacaseseriesofthreepatients AT wangliangchun dupilumabanemergingtherapeuticchoiceforrecalcitrantsubepidermalautoimmunebullousdiseasesacaseseriesofthreepatients AT shizhenrui dupilumabanemergingtherapeuticchoiceforrecalcitrantsubepidermalautoimmunebullousdiseasesacaseseriesofthreepatients |